|
|
Post by mnholdem on Nov 20, 2015 21:15:34 GMT -5
Frankly, if you want somebody to explain why a particular active pharmaceutical ingredient will work using a Technosphere-delivered dry formulation, there are few better than Hakan Edstrom. As Chief Operating Officer for MannKind Corporation for many years, Hakan was instrumental in the development of Technosphere Insulin (aka Afrezza) which could usher in a new diabetes treatment that may become more disruptive than anything that the medical community has seen introduced since the insulin pump.
I post this message to acknowledge Hakan Edstrom’s role in bringing Afrezza to market and for his leadership that led to FDA approval of Afrezza and the Technosphere drug delivery platform itself. I hope Edstrom's parting, even if not amicable, has the Board of Directors acknowledging the tremendous contribution Hakan has made to this company.
With the development of the Technosphere drug delivery platform, MannKind Corporation thrust itself into the big league. I believe they simply were not prepared for the scale of what they accomplished. This isn’t a single device or drug for which MannKind sought a collaborative partner or buyer, only to move on to the next invention. On the contrary, MannKind Corporation now commands a technology that has applications which can span nearly every disease known to humankind, in large part because of Edstrom’s leadership as COO.
While achieving this technological success, MannKind also put itself in a position where it needs a new type of leader.
Negotiating with giant global pharmaceutical companies over the future of potential blockbuster drugs brings with it the need for a CEO who is experienced in this multi-$billion arena. Frankly, even the venerable Alfred E. Mann, with his decades of experience in developing and selling medical devices, might have been largely unprepared for the challenges of drug development within a public corporation that promises disruptive drug treatment on such a massive scale.
A new kind of CEO is needed. The future of MannKind Corporation lies not only in its ability to market itself and the potential of its Technosphere delivery platform. The future of this company also lies in its ability to negotiate with and appeal to pharmaceutical companies over a wide range of drugs. That will take a CEO with vision and experience.
---
To Hakan Edstrom:
I simply say “thank you” for what you have accomplished. Wherever your road takes you from here, may you encounter success and prosperity.
Good fortune to you, friend.
|
|
|
|
Post by benyiju on Nov 20, 2015 22:12:49 GMT -5
Well put, MN. Lycka till, Hakan!
|
|
|
|
Post by parrerob on Nov 21, 2015 6:00:01 GMT -5
Frankly, if you want somebody to explain why a particular active pharmaceutical ingredient will work using a Technosphere-delivered dry formulation, there are few better than Hakan Edstrom. As Chief Operating Officer for MannKind Corporation for many years, Hakan was instrumental in the development of Technosphere Insulin (aka Afrezza) which could usher in a new diabetes treatment that may become more disruptive than anything that the medical community has seen introduced since the insulin pump.
I post this message to acknowledge Hakan Edstrom’s role in bringing Afrezza to market and for his leadership that led to FDA approval of Afrezza and the Technosphere drug delivery platform itself. I hope Edstrom's parting, even if not amicable, has the Board of Directors acknowledging the tremendous contribution Hakan has made to this company.
With the development of the Technosphere drug delivery platform, MannKind Corporation thrust itself into the big league. I believe they simply were not prepared for the scale of what they accomplished. This isn’t a single device or drug for which MannKind sought a collaborative partner or buyer, only to move on to the next invention. On the contrary, MannKind Corporation now commands a technology that has applications which can span nearly every disease known to humankind, in large part because of Edstrom’s leadership as COO.
While achieving this technological success, MannKind also put itself in a position where it needs a new type of leader.
Negotiating with giant global pharmaceutical companies over the future of potential blockbuster drugs brings with it the need for a CEO who is experienced in this multi-$billion arena. Frankly, even the venerable Alfred E. Mann, with his decades of experience in developing and selling medical devices, might have been largely unprepared for the challenges of drug development within a public corporation that promises disruptive drug treatment on such a massive scale.
A new kind of CEO is needed. The future of MannKind Corporation lies not only in its ability to market itself and the potential of its Technosphere delivery platform. The future of this company also lies in its ability to negotiate with and appeal to pharmaceutical companies over a wide range of drugs. That will take a CEO with vision and experience.
---
To Hakan Edstrom:
I simply say “thank you” for what you have accomplished. Wherever your road takes you from here, may you encounter success and prosperity.
Good fortune to you, friend.
MN, is it used in US a comunication like that, I mean the MNKD press release ? In Europe, normally We use to thanks the manager for the job done, specially after so many years, in a standard press release. MKND press release is so cool.... |
|
|
|
Post by lakers on Nov 21, 2015 11:19:50 GMT -5
A Class Act, you represent MN well , Mr. Holdem !
|
|
|
|
Post by mssciguy on Nov 21, 2015 11:25:42 GMT -5
A new kind of CEO may be needed at SNY, too. Just sayin'
|
|
|
|
Post by slugworth008 on Nov 21, 2015 22:57:37 GMT -5
Well damn said mn. Indeed - well stated sir. I wish MNKD would have published something so well written.
|
|
|
|
Post by slugworth008 on Nov 21, 2015 22:58:53 GMT -5
If SNY's PPS keeps tanking they will have another CEO...and soon IMO. Of course they are going to buy KERX and RLYP - LMFAO....that will help the bottom line.
|
|
|
|
Post by suebeeee1 on Nov 22, 2015 8:56:38 GMT -5
Well damn said mn. Indeed - well stated sir. I wish MNKD would have published something so well written. He must have screwed up royally for them not to have issued any kind of thank you. |
|
|
|
Post by daduke38 on Nov 22, 2015 10:15:37 GMT -5
Well put MN. The one thing I have recognized in my MNKD journey is that there are a bunch of good, compassionate , and intelligent people that have invested in this. And I think that what you stated hit's the nail on the head.
I am disappointed that MNKD has not recognized him through a nice PR. Al worked with this guy for how many years? Was it any secret that what you state isn't true? Has Al Mann and the BOD not been aware of the problems and loss of PPS? Al Mann has lost on paper over a Billion $'s since approval. Surely he has had to be aware, to state the obvious.
Personally, I have no idea whether he was forced out or just said "Who needs this?"!
Hakan is 65, I am sure financially set for life, and with the insurance issues, lung test, SNY's performance, etc. it had to be stressful for anyone, much less a person who was put in to a position that he didn't have the skill set for. He helped develop what is a life changing treatment for those who have been lucky enough to get it. Does Afrezza work? Without a doubt!!!!!!!!!!!!!!
This may have been simply a case of a man tired of banging his head against the wall and being criticized every step of the way.
I have read a ton of speculations and hopefully one of the positive ones are right. But there is no doubt in my mind that BP and the rigged FDA do not want this out there.
Was the 3rd quarter CC a disaster? Yeah, it was. Even Matt didn't sound great.
If Hakan is to be the scapegoat, then I have to say I have lost a bit of respect for Dr. Mann. He signed the agreement and went off to another venture. If he is healthy enough to come back on an interim basis, maybe he should have maintained the position for the first year. And honestly, who knows, we might be at the same place.
I am hoping for all investors and diabetics that this eventually works. But to blame Hakan when so many unanticipated issues have arisen, is just plain wrong.
|
|
|
|
Post by slugworth008 on Nov 22, 2015 10:18:53 GMT -5
@suebee
He must have screwed up royally for them not to have issued any kind of thank you.
------------------------------------
No doubt - and or - Al or the BOD didn't believe he was the right person to negotiate a possibly sister company agreement with TEVA?
But as usual it's all speculation because no one knows what in the wide, wide world of sports is going on.
But as daduke posted: Yes, he should have been recognized for the exceptional work he did accomplish. IMO
And I also agree with Daduke that BP and the rigged FDA don't want Afrezza out there. However, I do believe that it's to late to squelch it - It's been released into the
wild and there are enough people using it and loving it for it to be bottled up. Slowed down yes, killed no. We can ALL thanks social media and the early adopters use
of social media for this.
|
|
|
|
Post by mssciguy on Nov 22, 2015 10:40:01 GMT -5
If SNY's PPS keeps tanking they will have another CEO...and soon IMO. Of course they are going to buy KERX and RLYP - LMFAO....that will help the bottom line. SNY borrowed billions for acquisitions and general corporate expenses not long ago. But that's not really the way to do acquisitions. Wait until something is successful to buy it out. That may be their approach with MNKD. What do you think of the PFE Allergan merger that includes evasion of US taxes by relocation to Ireland? Are they trying to sneak this through during a lame duck presidency? As far as Afrezza goes, let's hope that SNY does a global expansion soon. Right now, the most literate and adaptable among PWD want it.... and generally they can afford it too... it's good press and generates good will among many doctors, nurses, pwd, just do it, SNY!!! |
|
|
|
Post by kbrion77 on Nov 22, 2015 11:18:03 GMT -5
I just feel like this in my own personal opinion signals that Afrezza will be sold off to SNY at some point soon. Hakan saw it through approval and has hopefully set up a first class manufacturing process for Afrezza. I believe their replacement CEO will be one that is a specialist in negotiating licensing deals since Technosphere is the future of MNKD. Looking forward to some significant developments in the next year!
|
|
|
|
Post by mssciguy on Nov 22, 2015 12:13:21 GMT -5
I just feel like this in my own personal opinion signals that Afrezza will be sold off to SNY at some point soon. Hakan saw it through approval and has hopefully set up a first class manufacturing process for Afrezza. I believe their replacement CEO will be one that is a specialist in negotiating licensing deals since Technosphere is the future of MNKD. Looking forward to some significant developments in the next year! Or Pfizer--- don't they have a presence in Connecticut? Yeah I think we'll see some action soon. Everything is positive except for price target by Goldman (somehow I often misspell the last four letters  ) which is disingenuous as they just tripled their long position and of course, except for the hit pieces and slow uptake by Doctors Without Spirometers. And of course the insurance which might turn positive with friendlier pricing. EAGERLY  awaiting choice of new CEO announcement. Was the TASE listing and Hakan stepping down almost simultaneously a coincidence? Oh and BTW, I don't think he was forced out. The time he spent at MNKD is a veritable career lifetime by today's standards. |
|
|
|
Post by kball on Nov 22, 2015 12:26:39 GMT -5
I just feel like this in my own personal opinion signals that Afrezza will be sold off to SNY at some point soon. Hakan saw it through approval and has hopefully set up a first class manufacturing process for Afrezza. I believe their replacement CEO will be one that is a specialist in negotiating licensing deals since Technosphere is the future of MNKD. Looking forward to some significant developments in the next year! Or Pfizer--- don't they have a presence in Connecticut? Yeah I think we'll see some action soon. Everything is positive except for price target by Goldman (somehow I often misspell the last four letters ) which is disingenuous as they just tripled their long position and of course, except for the hit pieces and slow uptake by Doctors Without Spirometers. And of course the insurance which might turn positive with friendlier pricing. EAGERLY awaiting choice of new CEO announcement. Was the TASE listing and Hakan stepping down almost simultaneously a coincidence? Oh and BTW, I don't think he was forced out. The time he spent at MNKD is a veritable career lifetime by today's standards. Considering it was Matt who was the face of the company on first day of Israeli exchange trading and not Hakan, I don't think it was coincidence but rather the separation was certainly being worked out dotting i's and crossing t's. (JMHO and i certainly have no actual insight) |
|
) which is disingenuous as they just tripled their long position and of course, except for the hit pieces and slow uptake by Doctors Without Spirometers. And of course the insurance which might turn positive with friendlier pricing.
awaiting choice of new CEO announcement. Was the TASE listing and Hakan stepping down almost simultaneously a coincidence? Oh and BTW, I don't think he was forced out. The time he spent at MNKD is a veritable career lifetime by today's standards.